ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Targacept, Inc." (TRGT) Report Updated: Sep 01, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Targacept, Inc." (TRGT)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: ENTA, FOLD, TKMR, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: F down downgrade
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Targacept, Inc."© quotemedia

Company Profile

Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder. The company’s small molecule products include TC-5619, which is under two separate Phase II clinical trials to treat negative symptoms and cognitive dysfunction in schizophrenia, inattentive-predominant attention deficit/hyperactivity disorder, and Alzheimer’s disease; AZD3480, a product under Phase IIb clinical trials for the treatment of mild to moderate Alzheimer’s disease; AZD1446 for treatment of Alzheimer’s disease; TC-6987 under Phase II clinical trials to treat asthma and type 2 diabetes; and TC-6499 for the treatment for gastrointestinal disorders. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation and Glaxo Group Limited to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.

Recent News: "Targacept, Inc."